Breakthrough Symptoms Remain an Unmet Need in Symptomatic Patients With Neuroendocrine Tumors and Carcinoid Syndrome.
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
01 01 2023
01 01 2023
Historique:
medline:
30
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
ppublish
Résumé
The aims of the study were to assess the effects of breakthrough carcinoid syndrome symptoms on well-being in neuroendocrine tumor (NET) patients insufficiently controlled on long-acting somatostatin analog (SSA) and to assess patient experience with treatment options, physician communication, and disease information sources. This study surveyed US NET patients from 2 online communities, experiencing at least one symptom, by utilizing a 64-item questionnaire. One hundred patients participated: 73% female, 75% age 56 to 75 years, and 93% White. Primary tumor distribution was as follows: gastrointestinal NET (n = 55), pancreatic NET (n = 33), lung NET (n = 11), and other NET (n = 13). All patients were actively treated with one long-acting SSA and experiencing breakthrough symptoms: diarrhea, flushing, or other (13% experienced one, 30% two, 57% greater than two). More than one third of treated patients experienced carcinoid-related symptoms daily. Sixty percent of respondents reported not having short-acting "rescue" treatment available, impacting well-being though anxiety or depression (45%), trouble exercising (65%), sleeping (57%), employment (54%), and maintaining friendships (43%). Breakthrough symptoms remain an unmet need, even in treated patients with NETs. Though still relying on physicians, NET patients are now also using the Internet. Improved awareness of optimal SSA use may improve syndrome control.
Identifiants
pubmed: 37378902
doi: 10.1097/MPA.0000000000002228
pii: 00006676-202301000-00009
doi:
Substances chimiques
Somatostatin
51110-01-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e70-e74Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
DeSantis CE, Kramer JL, Jemal A. The burden of rare cancers in the United States. CA Cancer J Clin . 2017;67:261–272.
Pinchot SN, Holen K, Sippel RS, et al. Carcinoid tumors. Oncologist . 2008;13:1255–1269.
Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas . 2013;42:557–577.
Ram P, Penalver JL, Lo KBU, et al. Carcinoid heart disease: review of current knowledge. Tex Heart Inst J . 2019;46:21–27.
Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes . 2018;25:22–35.
Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol . 2017;18:525–534.
Beaumont JL, Cella D, Phan AT, et al. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas . 2012;41:461–466.
Chau I, Casciano R, Willet J, et al. Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review. Eur J Cancer Care (Engl) . 2013;22:714–725.
Xiao C, Polomano R, Bruner DW. Comparison between patient-reported and clinician-observed symptoms in oncology. Cancer Nurs . 2013;36:E1–E16.
Mesa RA, Miller CB, Thyne M, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: findings from the MPN Landmark survey. Cancer . 2017;123:449–458.
Link-Age Connect Consultancy. 2019 Technology Survey, Older Adults—Age 55–100, April 2019. Available at: https://www.linkageconnect.com/wp-content/uploads/2019-Link-age-Connect-Technology-Study-Report.pdf . Accessed October 14, 2020.
Murfin G. Insights: patient-doctor relationship, survey results, The Healing NET Foundation, Unpublished Study, October, 2015.